| 1.755 0.035 (2.03%) | 10-08 14:29 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.33  |
1-year : | 2.58 |
| Resists | First : | 1.99 |
Second : | 2.21 |
| Pivot price | 1.75 |
|||
| Supports | First : | 1.65 | Second : | 1.38 |
| MAs | MA(5) : | 1.7  |
MA(20) : | 1.82 |
| MA(100) : | 1.98 |
MA(250) : | 1.9 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 17 |
D(3) : | 10.7 |
| RSI | RSI(14): 38.3 |
|||
| 52-week | High : | 2.58 | Low : | 1.21 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CERS ] has closed above bottom band by 49.2%. Bollinger Bands are 59.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.83 - 1.84 | 1.84 - 1.85 |
| Low: | 1.66 - 1.67 | 1.67 - 1.68 |
| Close: | 1.7 - 1.72 | 1.72 - 1.73 |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Thu, 26 Sep 2024
Cerus Corporation (NASDAQ:CERS) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
Wed, 25 Sep 2024
With 65% ownership, Cerus Corporation (NASDAQ:CERS) boasts of strong institutional backing - Yahoo Finance
Tue, 24 Sep 2024
Hood River Capital Management LLC Increases Holdings in Cerus Co. (NASDAQ:CERS) - MarketBeat
Thu, 05 Sep 2024
Insider Selling: CFO Kevin Green Sells 82,657 Shares of Cerus Corp (CERS) By GuruFocus - Investing.com Canada
Sun, 04 Aug 2024
Analysts Are Upgrading Cerus Corporation (NASDAQ:CERS) After Its Latest Results - Simply Wall St
Thu, 01 Aug 2024
Cerus Corp (CERS) Q2 2024 Earnings: EPS of -$0.03 Beats Estimates, Revenue of $50.5M Surpasses Expectations - GuruFocus.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 185 (M) |
| Shares Float | 157 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 75.9 (%) |
| Shares Short | 6,630 (K) |
| Shares Short P.Month | 6,380 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | -14.2 % |
| Operating Margin | -8.6 % |
| Return on Assets (ttm) | -4.8 % |
| Return on Equity (ttm) | -47.4 % |
| Qtrly Rev. Growth | 16 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.91 |
| EBITDA (p.s.) | -0.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -13.47 |
| PEG Ratio | 0 |
| Price to Book value | 6.48 |
| Price to Sales | 1.9 |
| Price to Cash Flow | -13.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|